Patent 8501730

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-flash

No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.

Cases on file (3)

Group view →

Specific litigation cases in our database that name US patent 8501730. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

US Patent 8501730 has been involved in several litigation cases. Here is a summary of the known litigation:

  1. Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. and Lupin Pharmaceuticals, Inc.

    • Plaintiff(s): Otsuka Pharmaceutical Co., Ltd.
    • Defendant(s): Lupin Ltd. and Lupin Pharmaceuticals, Inc.
    • Jurisdiction: Court of Appeals for the Federal Circuit (CAFC) (Case No. 24-2297) and U.S. District Court for the District of Delaware (Civ. No. 21-900-RGA)
    • Filing Date: The appeal to the CAFC was docketed on September 10, 2024. The District Court case was filed in 2021.
    • Outcome/Current Status:
      • CAFC (24-2297): On May 21, 2026, a Federal Circuit panel affirmed the lower court's judgment. It was determined that Lupin's tolvaptan ANDA process does not infringe US Patent 8501730 and that the asserted method claims of the patent are invalid as obvious over a 1999 synthesis paper by Kondo.
      • District of Delaware (21-900-RGA): The District Court found that Lupin did not infringe the patents-in-suit. While the asserted claims of a related patent (US8273735) were found obvious, the asserted claims of US Patent 8501730 were found not invalid by the District Court. This decision was published on July 31, 2024.

  2. Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc.

    • Plaintiff(s): Otsuka Pharmaceutical Co. Ltd.
    • Defendant(s): Par Pharmaceutical Inc.
    • Jurisdiction: District of Delaware
    • Case Number: 1:13-cv-01979
    • Filing Date: November 26, 2013.
    • Outcome/Current Status: The outcome of this specific case is not explicitly detailed in the provided information, but Par Pharmaceutical has been involved in other patent litigation with Takeda Pharmaceutical Company Ltd. in an antitrust suit regarding generic Amitiza.

  3. Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al.

It is worth noting that Google Patents also lists several other cases filed in the Delaware District Court related to US Patent 8501730, though specific details like plaintiffs, defendants, and outcomes are not provided for all of them within the available data:

  • 1:15-cv-00109
  • 1:18-cv-00972
  • 1:26-cv-00181
  • 1:25-cv-00318
  • 1:24-cv-00740
  • 1:14-cv-00789
  • 1:23-cv-00710
  • 1:22-cv-00513
  • 1:22-cv-00316

Generated 5/22/2026, 12:45:34 AM